Quest Partners LLC Boosts Holdings in Zynex, Inc. (NASDAQ:ZYXI)

Quest Partners LLC increased its position in Zynex, Inc. (NASDAQ:ZYXI) by 131.3% in the 3rd quarter, Holdings Channel reports. The firm owned 29,898 shares of the company’s stock after buying an additional 16,972 shares during the period. Quest Partners LLC’s holdings in Zynex were worth $244,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in ZYXI. Gladius Capital Management LP increased its position in Zynex by 53.4% during the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after buying an additional 1,742 shares during the period. Royce & Associates LP increased its holdings in shares of Zynex by 9.2% in the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock valued at $2,099,000 after acquiring an additional 21,781 shares during the period. GSA Capital Partners LLP raised its position in Zynex by 72.7% in the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after purchasing an additional 33,649 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Zynex by 22.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock worth $1,179,000 after purchasing an additional 26,368 shares during the period. Finally, Investment Partners Asset Management Inc. purchased a new position in Zynex during the 3rd quarter worth $96,000. 29.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $8.59, for a total value of $85,900.00. Following the completion of the sale, the chief financial officer now owns 44,878 shares in the company, valued at $385,502.02. This trade represents a 18.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 24,000 shares of company stock worth $208,440 over the last three months. 52.13% of the stock is currently owned by corporate insiders.

Zynex Stock Down 0.1 %

Shares of Zynex stock opened at $8.33 on Wednesday. The company has a market cap of $265.31 million, a P/E ratio of 55.53 and a beta of 0.53. The firm has a fifty day moving average of $8.24 and a two-hundred day moving average of $8.71. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a one year low of $7.15 and a one year high of $13.77.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same quarter last year, the firm earned $0.10 earnings per share. The firm’s revenue was up .1% compared to the same quarter last year. On average, analysts forecast that Zynex, Inc. will post 0.2 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ZYXI shares. HC Wainwright increased their target price on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada lowered their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.